Back to the drug test guide

Ketamine Test Evidence

Depends on the Brand of Test

Quetiapine

Source Liu et al., J Formos Med Assoc 2017

What It Found

  • Two patients taking quetiapine screened positive for ketamine, and both results failed confirmation.

Keep in Mind

  • The case report abstract does not identify the screen or establish that quetiapine caused the signal.

Test Studied

  • Urine ketamine screen in a two-patient report

Source ARK Ketamine II Assay. Export package insert, revision 4, 2026

What It Found

  • In a separate manufacturer study, urine spiked with quetiapine tested negative on ARK Ketamine II at both cutoffs.

Keep in Mind

  • ARK tested 100,000 ng/mL of quetiapine at ketamine cutoffs of 50 and 100 ng/mL.

Test Studied

  • ARK Ketamine II laboratory testing

The Test Is Made to Find It

Ketamine

Source Adamowicz and Kala, J Anal Toxicol 2005

What It Found

  • After children received ketamine for anesthesia, investigators detected ketamine and norketamine in urine.

Keep in Mind

  • A ketamine-positive urine result alone cannot distinguish medical from other exposure.

Test Studied

  • Targeted urine ketamine and norketamine testing by GC-MS and LC-MS

Source ARK Ketamine II Assay. Export package insert, revision 4, 2026

What It Found

  • The ARK screening assay also responds to norketamine and dehydronorketamine.

Test Studied

  • ARK Ketamine II urine immunoassay

Source Harun et al., J Anal Toxicol 2009

What It Found

  • Norketamine at 200 ng/mL exhibited 2.1% cross-reactivity in the ketamine assay.
  • Ketamine and its metabolite were identified in 34 tested urine specimens.

Keep in Mind

  • The ketamine screen responds predominantly to parent drug on this reagent.

Test Studied

  • Neogen ketamine urine microplate ELISA, compared with LC-MS/MS

2 sources ARK Ketamine II Assay. Export package insert, revision 4, 2026 Harun et al., J Anal Toxicol 2009

Keep in Mind

  • The contribution of each metabolite depends on the test.

Esketamine

Source ARK Ketamine II Assay. Export package insert, revision 4, 2026

What It Found

  • Esketamine is the S form of ketamine.
  • In spiked urine, 2,000 and 4,000 ng/mL of S-ketamine reached the respective 50 and 100 ng/mL assay cutoffs.
  • The manufacturer measured 2.5% reactivity for S-ketamine at both cutoffs.

Keep in Mind

  • The experiment tested the parent drug in urine.
  • It cannot predict the result after a particular nasal dose or account for all urinary metabolites.

Test Studied

  • ARK Ketamine II urine immunoassay, 50 and 100 ng/mL cutoffs

Tested: No False Positive Found

Amphetamine

Source Harun et al., J Anal Toxicol 2009

What It Found

  • The tested Amphetamine challenge produced no response at 10,000 ng/mL.

Keep in Mind

  • The paper identifies the standard as amphetamine without specifying an isomer or testing a marketed formulation.

Test Studied

  • Neogen ketamine microplate urine ELISA, study specificity challenge

Cocaine (medical topical use)

Source Harun et al., J Anal Toxicol 2009

What It Found

  • Both cocaine and benzoylecgonine showed no cross-reactivity at 10,000 ng/mL in the Neogen ketamine assay.

Keep in Mind

  • These were chemical standards.
  • The study did not test urine following topical medical cocaine administration.

Test Studied

  • Neogen ketamine microplate urine ELISA, study specificity challenge

Dextromethorphan

Source ARK Ketamine II Assay. Export package insert, revision 4, 2026

What It Found

  • Urine spiked with dextromethorphan at 100,000 ng/mL remained negative at both ketamine cutoffs in the manufacturer’s testing.

Keep in Mind

  • The finding concerns the parent compound on this ketamine assay.
  • Results on a phencyclidine (PCP) screen are a separate question.

Test Studied

  • ARK Ketamine II urine immunoassay, 50 and 100 ng/mL cutoffs

Diazepam

Source Harun et al., J Anal Toxicol 2009

What It Found

  • The tested Diazepam challenge produced no response at 10,000 ng/mL.

Keep in Mind

  • The result applies to this ketamine ELISA and the specified compound or metabolite.

Test Studied

  • Neogen ketamine microplate urine ELISA, study specificity challenge

Heroin

Source Harun et al., J Anal Toxicol 2009

What It Found

  • The tested heroin metabolite, 6-monoacetylmorphine, showed no cross-reactivity at 10,000 ng/mL.

Keep in Mind

  • Only the heroin metabolite 6-acetylmorphine (6-MAM) was tested.
  • The experiment gives no direct result for the parent drug.

Test Studied

  • Neogen ketamine microplate urine ELISA, study specificity challenge

Lamotrigine

Source ARK Ketamine II Assay. Export package insert, revision 4, 2026

What It Found

  • Urine spiked with lamotrigine at 100,000 ng/mL remained negative at both ketamine cutoffs in the manufacturer’s testing.

Keep in Mind

  • The finding concerns the parent compound on this ketamine assay.
  • Results on a phencyclidine (PCP) screen are a separate question.

Test Studied

  • ARK Ketamine II urine immunoassay, 50 and 100 ng/mL cutoffs

MDA

Source Harun et al., J Anal Toxicol 2009

What It Found

  • The tested MDA challenge produced no response at 10,000 ng/mL.

Keep in Mind

  • The result applies to this ketamine ELISA and the specified compound or metabolite.

Test Studied

  • Neogen ketamine microplate urine ELISA, study specificity challenge

MDEA

Source Harun et al., J Anal Toxicol 2009

What It Found

  • The tested MDEA challenge produced no response at 10,000 ng/mL.

Keep in Mind

  • The result applies to this ketamine ELISA and the specified compound or metabolite.

Test Studied

  • Neogen ketamine microplate urine ELISA, study specificity challenge

MDMA

Source Harun et al., J Anal Toxicol 2009

What It Found

  • The tested MDMA challenge produced no response at 10,000 ng/mL.

Keep in Mind

  • The result applies to this ketamine ELISA and the specified compound or metabolite.

Test Studied

  • Neogen ketamine microplate urine ELISA, study specificity challenge

Methadone

Source Harun et al., J Anal Toxicol 2009

What It Found

  • The tested Methadone challenge produced no response at 10,000 ng/mL.

Keep in Mind

  • The result applies to this ketamine ELISA and the specified compound or metabolite.

Test Studied

  • Neogen ketamine microplate urine ELISA, study specificity challenge

Methamphetamine

Source Harun et al., J Anal Toxicol 2009

What It Found

  • Methamphetamine showed no cross-reactivity at 10,000 ng/mL in the Neogen ketamine assay.

Keep in Mind

  • The result applies to this ketamine ELISA and the specified compound or metabolite.

Test Studied

  • Neogen ketamine microplate urine ELISA, study specificity challenge

Morphine

Source Harun et al., J Anal Toxicol 2009

What It Found

  • The tested Morphine challenge produced no response at 10,000 ng/mL.

Keep in Mind

  • The result applies to this ketamine ELISA and the specified compound or metabolite.

Test Studied

  • Neogen ketamine microplate urine ELISA, study specificity challenge

Phencyclidine

Source Harun et al., J Anal Toxicol 2009

What It Found

  • The tested Phencyclidine challenge produced no response at 10,000 ng/mL.

Keep in Mind

  • The result applies to this ketamine ELISA and the specified compound or metabolite.

Test Studied

  • Neogen ketamine microplate urine ELISA, study specificity challenge

Tiletamine

Source Harun et al., J Anal Toxicol 2009

What It Found

  • The tested Tiletamine challenge produced no response at 10,000 ng/mL.

Keep in Mind

  • The result applies to this ketamine ELISA and the specified compound or metabolite.

Test Studied

  • Neogen ketamine microplate urine ELISA, study specificity challenge

Venlafaxine

Source ARK Ketamine II Assay. Export package insert, revision 4, 2026

What It Found

  • Urine spiked with venlafaxine at 100,000 ng/mL remained negative at both ketamine cutoffs in the manufacturer’s testing.

Keep in Mind

  • The finding concerns the parent compound on this ketamine assay.
  • Results on a phencyclidine (PCP) screen are a separate question.

Test Studied

  • ARK Ketamine II urine immunoassay, 50 and 100 ng/mL cutoffs